MAXCYTE INC (MXCT) Stock News

USA - NASDAQ:MXCT - US57777K1060 - Common Stock

1.57 USD

-0.01 (-0.63%)

Last: 11/17/2025, 9:56:19 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

MXCT Latest News, Press Relases and Analysis

All

Press Releases

5 days ago - By: MaxCyte, Inc

MaxCyte Announces Planned CFO Transition in 2026

5 days ago - By: MaxCyte, Inc

MaxCyte Announces Planned CFO Transition in 2026

5 days ago - By: MaxCyte, Inc

MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance

5 days ago - By: MaxCyte, Inc

MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance

6 days ago - By: Benzinga

Insights into MaxCyte's Upcoming Earnings

12 days ago - By: Benzinga - Mentions: TECH INSE GEF SKYT ...

Earnings Scheduled For November 5, 2025

3 months ago - By: The Motley Fool

MaxCyte (MXCT) Q2 Revenue Drops 18%

7 days ago - By: Zacks Investment Research - Mentions: RNA

Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Beats Revenue Estimates

10 days ago - By: Zacks Investment Research - Mentions: ANIP

ANI Pharmaceuticals (ANIP) Q3 Earnings and Revenues Beat Estimates

12 days ago - By: MaxCyte, Inc

MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance

12 days ago - By: MaxCyte, Inc

MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance

a month ago - By: MaxCyte, Inc

MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025

a month ago - By: MaxCyte, Inc

MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025

a month ago - By: MaxCyte, Inc

MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors

a month ago - By: MaxCyte, Inc

MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors

2 months ago - By: MaxCyte, Inc

MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability

2 months ago - By: MaxCyte, Inc

MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability

3 months ago - By: Yahoo Finance - Mentions: ACET

MaxCyte (MXCT) Signed a Strategic Platform License with Adicet Bio

3 months ago - By: Zacks Investment Research - Mentions: IOVA

MaxCyte, Inc. (MXCT) Reports Q2 Loss, Misses Revenue Estimates

3 months ago - By: MaxCyte, Inc

MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance

4 months ago - By: MaxCyte, Inc

MaxCyte Signs Platform License Agreement with Adicet Bio

4 months ago - By: MaxCyte, Inc

MaxCyte Signs Platform License Agreement with Adicet Bio

4 months ago - By: MaxCyte, Inc

MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline

4 months ago - By: MaxCyte, Inc

MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline

4 months ago - By: MaxCyte, Inc

MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025

4 months ago - By: MaxCyte, Inc

MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025

5 months ago - By: MaxCyte, Inc

MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies

5 months ago - By: MaxCyte, Inc

MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies

6 months ago - By: Yahoo Finance - Mentions: DHI CMG

MaxCyte, Inc. (MXCT): A Bull Case Theory

6 months ago - By: Zacks Investment Research - Mentions: CUE

MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates

6 months ago - By: MaxCyte, Inc

MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance